Karenza Alexis
Daiichi Sankyo (United States)(US)
Publications by Year
Research Areas
CAR-T cell therapy research, Lymphoma Diagnosis and Treatment, Cancer Treatment and Pharmacology, Economic and Financial Impacts of Cancer, Immune Cell Function and Interaction
Most-Cited Works
- → Ethnic Neutropenia and Treatment Delay in African American Women Undergoing Chemotherapy for Early-Stage Breast Cancer(2003)155 cited
- → 36-Year-Old Female with Catastrophic Antiphospholipid Syndrome Treated with Eculizumab: A Case Report and Review of Literature(2014)85 cited
- → High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study(2020)77 cited
- → Innate Cell Engager AFM13 Combined with Preactivated and Expanded Cord Blood-Derived NK Cells for Patients with Double Refractory CD30+ Lymphoma(2022)23 cited
- → Innate Cell Engager (ICE®) AFM13 Combined with Preactivated and Expanded (P+E) Cord Blood (CB)-Derived Natural Killer (NK) Cells for Patients with Refractory CD30-Positive Lymphomas: Final Results(2023)19 cited
- → Observational Study of Clinical Outcomes of Eribulin Mesylate in Metastatic Breast Cancer After Cyclin-Dependent Kinase 4/6 Inhibitor Therapy(2019)17 cited
- → Abstract CT003: Innate cell engager (ICE®) AFM13 combined with preactivated and expanded cord blood (CB)-derived NK cells for patients with refractory/relapsed CD30+ lymphoma(2022)16 cited
- → Abstract CT024: REDIRECT: A Phase 2 study of AFM13 in patients with CD30-positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL)(2023)14 cited
- → Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis(2020)13 cited
- → Acquired Von Willebrand’s Syndrome in Systemic Lupus Erythematosus(2014)11 cited